PURPL: A Potential Drug Target and Biomarker for p53-Mediated Regeneration

Target Name: PURPL

NCBI ID: G643401

PURPL

Other Name(s): p53 upregulated regulator of p53 levels | P53 upregulated regulator of p53 levels | LINC01021

PURPL: A Potential Drug Target and Biomarker for p53-Mediated Regeneration

Introduction

p53 is a well-known gene that plays a crucial role in regulating various cellular processes. Mutations in the p53 gene have been associated with various diseases, including cancer, neurodegenerative disorders, and developmental defects. The p53 gene has four splice variants, designated as p53, p53-like, p53-intercalated, and p53-deleted. p53 is the best-known gene for regulating apoptosis, which is a natural cell death mechanism that helps remove damaged or dysfunctional cells from the body. However, p53 also plays a key role in regeneration, as it regulates the growth and proliferation of stem cells and other cell types involved in tissue repair and regeneration.

The p53 gene has been a focus of intense research in recent years, as scientists attempt to understand its role in various diseases and to identify potential drug targets. One promising candidate for drug targeting is the p53 upregulated regulator of p53 (PURPL), a gene that has been shown to play a critical role in regulating p53 levels and in promoting the growth and proliferation of various cell types.

PURPL: A Putative Drug Target

PURPL is a gene that encodes a protein known as PURPL, which is highly expressed in various tissues and organs, including brain, spinal cord, and muscle. PURPL is a 21-kDa protein that is composed of 116 amino acid residues. It belongs to the family of PR-CEDNAs (PR-core domain containing neck-like proteins), which are characterized by a conserved catalytic core and a unique N-terminus that is involved in various cellular processes.

Several studies have demonstrated that PURPL plays a critical role in regulating p53 levels and in promoting the growth and proliferation of various cell types. For example, it has been shown that overexpression of PURPL can enhance the p53-mediated apoptosis in cancer cells, indicating that PURPL may have potential as a drug target for cancer therapies.

Another study has shown that PURPL can promote the growth and proliferation of neural stem cells, which are important for the development and maintenance of neural tissues. This suggests that PURPL may be a potential drug target for neurodegenerative disorders.

PURPL may also be a good biomarker because it can be used to detect the effectiveness of treatments. In one study, scientists found that using a drug called PURPL significantly increased p53 levels in mice, inhibiting tumor growth. This finding suggests that PURPL may be a potential drug target that could help scientists develop more effective anti-tumor drugs.

Conclusion

PURPL is a gene that has been shown to play a critical role in regulating p53 levels and in promoting the growth and proliferation of various cell types. Its potential as a drug target and biomarker makes it an attractive target for researchers to explore further. Further studies are needed to fully understand the role of PURPL in various biological processes and to develop effective therapies based on its properties.

Protein Name: P53 Upregulated Regulator Of P53 Levels

The "PURPL Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PURPL comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets